Cargando…

Efficacy of Oral APX001 in a Murine Model of Cryptococcal Meningitis

BACKGROUND: APX001 is a first-in-class intravenous and orally available broad spectrum antifungal inhibitor of Gwt1, a protein involved in glycosylphosphatidylinositol anchor biosynthesis. This study evaluated efficacy of APX001, alone and in combination with fluconazole (FCN), in a mouse model of c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schell, Wiley A, Giamberardino, Charles, Shaw, Karen J, Perfect, John R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630770/ http://dx.doi.org/10.1093/ofid/ofx163.1225

Ejemplares similares

Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis
por: Giamberardino, Charles D., et al.
Publicado: (2022)

In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
por: Shaw, Karen Joy, et al.
Publicado: (2018)

168. Efficacy of the Novel gwt1 Inhibitor APX2039 in a Rabbit Model of cryptococcus Meningitis
por: Shaw, Karen J, et al.
Publicado: (2020)

Evaluation of the In Vitro and In Vivo Antifungal Activity of APX001A/APX001 Against Candida auris
por: Larkin, Emily, et al.
Publicado: (2017)

In Vitro Characterization of the Neurapheresis™ System for the Treatment of Cryptococcal Meningitis
por: Charalambous, Lefko, et al.
Publicado: (2017)

APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

726. APX001 (Fosmanogepix) Is Effective in an Immunosuppressed Mouse Model of Rhizopus oryzae Infection
por: Gebremariam, Teklegiorgis, et al.
Publicado: (2019)

1954. In vivo Efficacy of Delayed Therapy with the Novel Inositol Acyltransferase Inhibitor Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
por: Wiederhold, Nathan P, et al.
Publicado: (2019)

678. Galactomannan Is a Biomarker of APX001 (Fosmanogepix) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis
por: Gebremariam, Teklegiorgis, et al.
Publicado: (2019)

In Vitro and In Vivo Evaluation of the Antifungal Activity of APX001A/APX001 against Candida auris
por: Hager, Christopher L., et al.
Publicado: (2018)

605. Efficacy and pharmacokinetics-pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis
por: Giamberardino, Charles D, et al.
Publicado: (2022)

Efficacy of Delayed Therapy with Fosmanogepix (APX001) in a Murine Model of Candida auris Invasive Candidiasis
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

APX001A Protects Immunosuppressed Mice from Rhizopus delemar Infection
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2017)

Absorption, Distribution, and Excretion of (14)C-APX001 after Single-Dose Administration to Rats and Monkeys
por: Mansbach, Robert, et al.
Publicado: (2017)

Fosmanogepix (APX001) Is Effective in the Treatment of Pulmonary Murine Mucormycosis Due to Rhizopus arrhizus
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2020)

Fungal Cytological Profiling of Candida albicans Exposed to Diverse Antifungal Agents Including the Novel Gwt1 inhibitor APX001A
por: Sharp, Marc, et al.
Publicado: (2017)

Galactomannan Is a Biomarker of Fosmanogepix (APX001) Efficacy in Treating Experimental Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
por: Trang, Michael, et al.
Publicado: (2018)

Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis
por: Giamberardino, Charles D., et al.
Publicado: (2023)

Hearing Loss in Cryptococcal Meningitis Survivors
por: Lofgren, Sarah, et al.
Publicado: (2017)

Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Candida Species
por: Kapoor, Mili, et al.
Publicado: (2019)

APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia
por: Viriyakosol, Suganya, et al.
Publicado: (2019)

Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance
por: Hope, William, et al.
Publicado: (2019)

869. Oral Encochleated Amphotericin B for Cryptococcal Meningitis: a Phase II Randomized Trial
por: Atukunda, Mucunguzi, et al.
Publicado: (2022)

Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis
por: Alkhazraji, Sondus, et al.
Publicado: (2020)

2052. Performance of the Biofire Filmarray Meningitis/Encephalitis Panel in Cryptococcal Meningitis Diagnosis
por: Walker, Morgan, et al.
Publicado: (2018)

Significantly Improved Pharmacokinetics Enhances In Vivo Efficacy of APX001 against Echinocandin- and Multidrug-Resistant Candida Isolates in a Mouse Model of Invasive Candidiasis
por: Zhao, Yanan, et al.
Publicado: (2018)

Pharmacodynamics of Isavuconazole in a Rabbit Model of Cryptococcal Meningoencephalitis
por: Kovanda, Laura L., et al.
Publicado: (2019)

Experimental Models of Short Courses of Liposomal Amphotericin B for Induction Therapy for Cryptococcal Meningitis
por: Lestner, Jodi, et al.
Publicado: (2017)

1614. Gwt1 Inhibitor, APX2104, Protects Against Invasive Aspergillosis in Neutropenic Mouse Model
por: Shaheen, Shareef, et al.
Publicado: (2020)

Feasibility of Neurapheresis™ as a Therapy for Multidrug Resistant Gram-negative Bacterial Meningitis
por: Ballard, Christi, et al.
Publicado: (2017)

1593 Predictors of Mortality for HIV-associated Cryptococcal Meningitis
por: Nimitvilai, Sireethorn, et al.
Publicado: (2014)

1717. Cryptococcal Meningitis: A Comparison of Clinical Features and Outcomes by HIV Status
por: Pate, Amy, et al.
Publicado: (2019)

Oral Presentations 001 - 053
Publicado: (2003)

1260. Activity of Manogepix (APX001A) against 2,669 Fungal Isolates from the SENTRY Surveillance Program (2018-2019) Stratified by Infection Type
por: Huband, Michael D, et al.
Publicado: (2020)

1716. Baseline Serum C-Reactive Protein Level Predicts Mortality in Cryptococcal Meningitis
por: Chesdachai, Supavit, et al.
Publicado: (2019)

Immunological study of an attenuated Salmonella Typhimurium expressing ApxIA, ApxIIA, ApxIIIA and OmpA of Actinobacillus pleuropneumoniae in a mouse model
por: HUR, Jin, et al.
Publicado: (2015)

Molecular mechanisms of cryptococcal meningitis
por: Liu, Tong-Bao, et al.
Publicado: (2012)

Cryptococcal meningitis complicating sarcoidosis
por: Leonhard, Sonja E., et al.
Publicado: (2016)

Cryptococcal Meningitis in an Apparent Immunocompetent Host
por: Molina, Guarina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0cksjket1pu1i5m2u0nu4mj0g4